Schizotypal Personality Disorder
Conditions
Keywords
schizotypy, psychotherapy, compassion-focused therapy, metacognitively oriented psychotherapy, metacognition, compassion
Brief summary
The purpose of this study is to assess the safety and efficacy of a newly developed psychotherapy for schizotypal personality disorder. This new form of psychotherapy integrates compassion focused therapy and metacognitively oriented psychotherapy.
Detailed description
After being informed about the study and potential risks, all patients giving written informed consent will undergo a psychological assessment so as to determine eligibility for study entry. Patients who meet the eligibility requirements will be randomized in a double-blind manner in a 1:1 ratio to new integrative psychotherapy or treatment as usual (cognitive behavioral therapy plus standard psychopharmacological treatment). One month after the conclusion of the two forms of treatment (both lasting 6 months), patients will have access to the final follow-up assessment.
Interventions
BEHAVIORALCompassion and Metacognition Based Therapy
The intervention is a Third Wave Cognitive Therapy targeting metacognitive dysfuctions (through Metacognitively Oriented Psychotherapy) and self-criticism (through Compassion Focused Therapy).
BEHAVIORALCognitive Behavioral Therapy
Standard Cognitive Behavioral Therapy for Personality Disorders plus Standard Psychopharmacological Treatment.
Sponsors
Tages Onlus
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
TRIPLE (Subject, Caregiver, Outcomes Assessor)
Intervention model description
Randomized Controlled Trial with Repeated Measures
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
\- Being diagnosed with Schizotypal Personality Disorder at SCID-5-AMPD
Exclusion criteria
* Being under psychotherapy or psychopahrnacological treatment * Being diagnosed with schizophrenia and other psychotic disorders * Being diagnosed with bipolar disorder * Being diagnosed with intelletual disability * Being diagnosed with any neurological disases
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Change from Baseline Personality Pathology at 8 months | 9 measurements over the course of 8 months: (i) at 1 month before intervention starts; (ii) once the treatment starts; (iii) 6 measurements at the end of each month of intervention; iv) at 1-month follow-up. | Decrese of Personality Inventory for DSM-5 - Brief Form (PID-5-BF) total score (with a range of 0 to 75; higher scores indicating a more severe psychopathology) from baseline to final assessment after 8 months. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Schizotypal Personality Disorder Diagnosis (SPD) | Pre-post evaluation between pre-assessment (1-month before the intervention) and 1-month follow-up assessment. | Recovery from SPD diagnosis at Module III of Structural Clinical Interview for DSM-5 Alternative Model of Personality Disorders (SCID-5-AMPD). |
| General Psychopathology | Pre-post evaluation between pre-assessment (1-month before the intervention) and 1-month follow-up assessment. | Decrease of Global Severity Index (with a range of 0 to 4; higher scores indicating a more severe psychopathology) of the Symptom Checklist-90-R (SCL-90-R). |
| Metacognition | Pre-post evaluation between pre-assessment (1-month before the intervention) and 1-month follow-up assessment. | Increase of Metacognition Assessment Scale - Abreviated (MAS-A) total score (with a range of 0 to 28; higher scores indicating higher metacognitive functioning). |
Countries
Italy
Outcome results
None listed